anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The incidental use of statins during radiation therapy has been associated with a reduced long-term risk of developing atherosclerotic cardiovascular disease. We examined whether irradiation causes chronic vascular injury and whether short-term administration of statins during and after irradiation is sufficient to prevent chronic injury compared with long-term administration.
METHODS AND RESULTS: C57Bl/6 mice were pretreated with pravastatin for 72 hours and then exposed to 12 Gy X-ray head-and-neck irradiation. Pravastatin was then administered either for an additional 24 hours or for 1 year. Carotid arteries were tested for vascular reactivity, altered gene expression, and collagen deposition 1 year after irradiation. Treatment with pravastatin for 24 hours after irradiation reduced the loss of endothelium-dependent vasorelaxation and protected against enhanced vasoconstriction. Expression of markers associated with inflammation (NFκB p65 [phospho-nuclear factor kappa B p65] and TNF-α [tumor necrosis factor alpha]) and with oxidative stress (NADPH oxidases 2 and 4) were lowered and subunits of the voltage and Ca2+ activated K+ BK channel (potassium calcium-activated channel subfamily M alpha 1 and potassium calcium-activated channel subfamily M regulatory beta subunit 1) in the carotid artery were modulated. Treatment with pravastatin for 1 year after irradiation completely reversed irradiation-induced changes.
CONCLUSIONS: Short-term administration of pravastatin is sufficient to reduce chronic vascular injury at 1 year after irradiation. Long-term administration eliminates the effects of irradiation. These findings suggest that a prospective treatment strategy involving statins could be effective in patients undergoing radiation therapy. The optimal duration of treatment in humans has yet to be determined.
CCDC88B is a risk factor for several chronic inflammatory diseases in humans and its inactivation causes a migratory defect in DCs in mice. CCDC88B belongs to a family of cytoskeleton-associated scaffold proteins that feature protein:protein interaction domains. Here, we identified the Rho/Rac Guanine Nucleotide Exchange Factor 2 (ARHGEF2) and the RAS Protein Activator Like 3 (RASAL3) as CCDC88B physical and functional interactors. Mice defective in Arhgef2 or Rasal3 show dampened neuroinflammation, and display altered cellular response and susceptibility to colitis; ARHGEF2 maps to a human Chromosome 1 locus associated with susceptibility to IBD. Arhgef2 and Rasal3 mutant DCs show altered migration and motility in vitro, causing either reduced (Arhgef2) or enhanced (Rasal3) migratory properties. The CCDC88B/RASAL3/ARHGEF2 complex appears to regulate DCs migration by modulating activation of RHOA, with ARHGEF2 and RASAL3 acting in opposite regulatory fashions, providing a molecular mechanism for the involvement of these proteins in DCs immune functions.
Participants received matching placebo at weeks 0, 1, 2, 3, 4, 8, and 12 by subcutaneous injection during blinded induction period followed by 250mg Mirikizumab Q4W from week 16 to 32 followed by 250mg Mirikizumab Q8W from week 32 to 48 in maintenance period. Participants received matching placebo to blind Secukinumab.
A 61-year-old woman presented at a nearby clinic with a complaint of a mass in the right axilla. Initial imaging examinations, including mammography, ultrasonography, and breast MRI, did not reveal any obvious intramammary lesions, although a swollen lymph node was observed in the right axilla. Fine-needle aspiration cytology confirmed malignancy. Hence, a core needle biopsy was performed. The results indicated a suspected metastasis of invasive ductal carcinoma(ER-, PgR-, HER2-); however, the primary tumor could not be definitively determined. Despite an extensive whole-body examination, the primary tumor remained unidentified. Nonetheless, metastasis of occult breast cancer in the right axillary lymph node was postulated. Subsequent axillary dissection revealed metastases in only one lymph node. Taking the clinical findings into consideration, the patient was diagnosed with right occult breast cancer, and chemotherapy and radiotherapy were planned.
PURPOSE: Tonsillectomy is a common surgery performed for indications such as chronic tonsilitis, tonsil hypertrophy and obsructive sleep apnea. Although posttonsillectomy bleeding (PTB) is rare and can be controlled with simple interventions in many patients, it is one of the most feared complications of tonsillectomy surgery. In our study, we investigated the effects of changes in hemogram and coagulation values and seasonal effects on PTB.
METHODS: Pediatric and adult patients who underwent tonsillectomy with cold knife method between August 2020 and August 2023 in our clinic were retrospectively reviewed. Demographic data, hemogram and coagulation values of the patients in the control and study groups were recorded and the differences between the two groups in terms of these parameters were evaluated.
RESULTS: Our study included 991 patients aged 1-51 years. The rate of PTB was calculated as 2.82%. No patient with primary PTB was found. The duration of bleeding development was 7.03 days. Age, WBC and neutrophil values were statistically significantly higher in the study group. There were no significant differences between two groups in terms of gender, season and other hemogram and coagulation parameters.
CONCLUSIONS: Age, high WBC and neutrophil levels were determined as possible risk factors for PTB. Seasonal and gender distribution, aPTT and INR values were similar in the two groups. In order to prevent and predict bleeding, detailed infection investigation should be performed and the risk of bleeding should be considered to increase with increasing age.
There has been a substantial increase in cancer survival rates in the the past decades, however many cancer survivors are now impacted by the multitude of toxicities associated with treatment. It is only when temporary toxicities subside that the long-term toxicities progress and become important. Chemotherapy, although highly effective, is known to cause ototoxicity, presenting as hearing loss and tinnitus. Hearing loss and tinnitus are associated with a higher risk of depression, dementia, social isolation and anxiety. There is little information and support offered to patients who suffer from ototoxicity, which can potentially lead to many being undiagnosed and untreated. Ototoxicity can be permanent and progressive, therefore it is essential that a deeper understanding and increased awareness of how hearing loss and tinnitus affects the quality of life (QoL) of cancer survivors can improve long-term symptoms Management and support offered.

This project aims to identify the prevalence and severity of long-term ototoxicity in cancer survivors following platinum-based treatment. Prevalence of ototoxicity can be unreliable and varies in the medical literature, with studies reporting rates between 24% and 79%. Information on prevalence will be achieved by recruiting patients from oncology clinics and performing a high frequency audiogram. The results from the audiogram will be compared to an normative dataset in addition to detecting self-reported hearing loss from the Hearing Handicap Inventory for Adults (HHIA) and the Hearing Handicap Inventory for Elderly (HHIE) questionnaires. Furthermore, the severity and prevalence of tinnitus will also be detected by using the Tinnitus Handicap Inventory (THI) questionnaire. A validated questionnaire assessing QoL (SF-36) after cancer will also be completed by the patients. The questionnaires will be statistically analysed and compared against a dataset from the general population in the hope to identify the concerns surrounding long-term ototoxicity in cancer survivors.
The invention provides pyridone derivatives represented by a general formula (I).    (see formula I) in the formula, R1 and R2 may be the same or different and stands for H. etc., or R1 and R2 form an aliphatic nitrogen-containing heterocyclic group together with N to which they bind; X1-X3 may be the same or different and stand for methine or N, provided not all of them all simultaneousely stand for nitrogen; X4-X7 may be the same or different and stand for methine or N, provided that three or more of them do not simultaneously stand for N; Y1 and Y3 may be the same or different and stand for single bond, -O-, -NR-, -S-etc.; Y2 stands for lower alkylene etc.; R stands for H, etc.; L stands for methylene; Z1 and Z2 may be the same or different and stand for single bond or lower alkylene; or R1, L and Z2 may form an aliphatic nitrogen-containing heterocyclic group with N to which R1 binds; and Ar stands for aromatic carbocyclic group. The invention further relates to pharmaceutical compositions comprising compounds of formula (I) and their use to antagonize melanine concentrating hormone receptor.
PURPOSE: A composition containing herb mixture extract for relieving hangover is provided to promote activation of ADH and ALDH and decomposition of alcohol and acetealdehyde. CONSTITUTION: A composition for relieving hangover contains Trapa japonica Flerov, Nelumbo nucifera Gaertn. seed, and Hovenia dulcis Thunb. fruit or seed extract as an active ingredient. The extract is contained in 0.01-95 weight%. The weight ratio of the Trapa japonica Flerov, Nelumbo nucifera Gaertn. seed, and Hovenia dulcis Thunb. fruit or seed is 1.0-8.0 : 0.75-3.0 : 1. A beverage for relieving hangover contains Trapa japonica Flerov, Nelumbo nucifera Gaertn. seed, and Hovenia dulcis Thunb. fruit or seed extract as an active ingredient.
Participants randomized to the immediate treatment condition will receive written and verbal feedback after the baseline assessment visit. These families will begin PCIT shortly after this visit. These families will participate in follow-up visits at 3 and 6 months after the baseline visit.
PURPOSE:To obtain a beaded inclusion compound having a high effective utility ratio because of high content and release ratio of guest compound and a small loss of guest compound in production process, comprising a crystal nucleus substance and/or a porous substance and an inclusion compound. CONSTITUTION:The title compound comprising a crystal nucleus substance (e.g. various kinds of porous substances such as porous glass, zeolite or active carbon) having 0.1-1mum particle diameter and/or a porous substance (preferably inorganic substance) having 1-100mum particle diameter and an inclusion compound. A volatile liquid, for example, aroma (e.g. lemon oil), natural purified oil (e.g. 1-menthol) or amine-based insecticide is preferable as a guest compound and a macromolecular compound (e.g. 1,1,6,6-tetraphenyl-2,4-hexadiyne-1,6-diol) is preferable as a host compound. The inclusion compound is produced by a method of simultaneous inclusion and granulation of the crystal nucleus substance and/or the porous substance, the host and guest compounds.
Provided are a chimeric lysozyme variant having improved heat resistance and a polynucleotide encoding the variant. A novel chimeric lysozyme sequence is constructed, and high-efficiency expression in a host cell is achieved. The thermal stability of the chimeric lysozyme under the condition of 60°C is nearly doubled compared to a parental sequence. Also provided is a use of the chimeric lysozyme variant. Also provided are an animal feed additive containing the chimeric lysozyme variant and an animal feed containing the animal feed additive. The feed additive has a significant effect on animal growth performance and greatly improves the conversion rate of the feed.
Canagliflozin is a drug that is being tested to see if it may be useful in treating patients diagnosed with type 2 diabetes mellitus (T2DM). This is a randomized (patients will assigned to 1 of 4 study treatments by chance), double-blind (neither the patient or the study doctor will know the name of the assigned treatment), study to assess the pharmacokinetics (blood levels) and pharmacodynamics (effects of the drug on the body) of canagliflozin compared to a placebo (a capsule that looks like all the other treatments but has no real medicine) in patients with T2DM. Approximately 36 patients with T2DM will receive once-daily treatment with canagliflozin (50 mg, 100 mg, or 300 mg doses) or placebo for 7 days. Patients will participate in the study for approximately 9 weeks. Blood and urine samples will be collected at specified times before and after each dose of study drug for pharmacokinetic and pharmacodynamic analyses. A blood sample will also be collected before the first dose of study drug for pharmacogenomic analysis (ie, genetic testing) for possible use in characterizing the safety and/or efficacy of study drug in relation to the patient pharmacogenic profile. During the study, the safety and tolerability of canagliflozin will be evaluated by monitoring adverse events and findings from laboratory evaluations, vital signs measurements, and ECG measurements. The primary outcome measure in the study is the concentration of canagliflozin and its major metabolites (M5 and M7) in the blood measured by protocol-specified pharmacokinetic parameters at protocol specified time points through Day 7. Study drug will be taken orally (by mouth) once daily before the first meal each day. On Day -1, patients will take 1 dose of placebo in single-blind fashion (patient blinded) to determine baseline assessments. After randomization, patients will take single doses of double-blind canagliflozin (50 mg, 100 mg, or 300 mg) or matching placebo once daily for 7 days (Day 1 through Day 7).
The invention discloses the use of human interleukin 32 in the preparation of medicaments for treating or preventing influenza A virus infection. Clones of splicing isoforms IL-32(alpha, beta, gamma, delta, epsilon and zeta) of IL-32 are cloned and established by using a molecular biological method; MDCK cells are transfected with the clones; and thus, the applicant has found that MDCK cells in which all subtypes of the human interleukin 32 are overexpressed are improved in resistance to influenza A viruses. Different IL-32 subtypes show different inhibition effects on the replication of the influenza A viruses. The IL-32 gamma has the most obvious anti-influenza A virus effect. And only the IL-32 gamma is of a secretor type. The human interleukin 32 is a critical antiviral gene in immunoreactions of a host. The applicant is the first one to put forward that the human interleukin 32 has an extremely effective anti-influenza A virus function and to point out that the human interleukin 32 has an application prospect in developing anti-influenza A virus medicaments for effectively preventing and treating influenza A virus infection.
This was a 6-month, multicenter, non-comparative, OLE study to evaluate the safety of long-term nabiximols use as an adjunctive measure in participants with advanced cancer. The study provided continued availability of nabiximols to participants who completed a preceding double-blind phase 3 study and de novo participants. Consenting eligible participants entered the extension study (Day 1) on the same day as the "end of treatment" visit of a parent study or within 7 days of the "end of treatment" visit or on the day of the "safety follow-up visit" of the parent study. The "safety follow-up" visit of a parent study was performed on the same day as Day 1, if the participant did not enter the OLE study on the same day as the "end of treatment" visit of a parent study. De novo participants attended a screening visit 3 to 14 days prior to enrollment (Day 1). All participants commenced dosing on Day 1. Further study visits took place after 2 weeks (Day 15), and every 4 weeks thereafter until the end of treatment period on Day 183 or earlier if the participant withdrew from the study.

Treatment was started as a single spray in the evening on the first day (Day 1). Participants then gradually titrated by 1 additional spray per day to an individualized dose, balancing efficacy and tolerability. Participants had to complete titration within 14 days of their first dose of study drug and then continue at the same dose for the remainder of the study.
TPF inductive chemotherapy plus Toripalimab for 3 cycles, and radiotherapy plus Toripalimab if the inductive treatment efficacy is CR or \>75%PR. If not, operation is suggested.
Obesity is a leading cause of morbidity and mortality globally. While the prevalence of obesity has been increasing, the incidence of its related complications including dyslipidemia and cardiovascular disease (CVD) has also been rising. Recent research has focused on modalities aimed at reducing obesity. Several modalities have been suggested including behavioral and dietary changes, medications, and bariatric surgery. These modalities differ in their effectiveness and invasiveness, with dietary changes gaining more interest due to their minimal risks compared to other modalities. Specifically, intermittent fasting (IF) has been gaining interest in the past decade. IF is characterized by cycles of alternating fasting and eating windows, with several different forms practiced. IF has been shown to reduce weight and alleviate obesity-related complications. Our review of clinical and experimental studies explores the effects of IF on the lipid profile, white adipose tissue (WAT) dynamics, and the gut microbiome. Notably, IF corrects dyslipidemia, reduces WAT accumulation, and decreases inflammation, which reduces CVD and obesity. This comprehensive analysis details the protective metabolic role of IF, advocating for its integration into public health practices.
Berbamine (Berbamine) is a dibenzyl isoquinoline alkaloid extracted from plants. At present, research on berbamine in the antidepressant field is not reported yet. The natural source and relatively low toxicity of berbamine make it a powerful candidate for the development of novel antidepressants. The application relates to application of berbamine or pharmaceutically acceptable salt thereof in preparation of a preparation for depression. The application exploits the clinical new indication application of the berbamine, and can be used for treating and relieving depressive mood disorder or depression. The inventor judges the anti-depression effect of the berbamine hydrochloride by the animal tail suspension and forced swimming immobility time in a classical depression animal model, and the result shows that the immobility time of a depression model mouse is shortened compared with the immobility time of a treatment group without gastric lavage in the treatment process of 2.5-10 mg/kg of gastric lavage, and especially the anti-depression effect is optimal in the mice of 5 mg/kg of berbamine hydrochloride.
Methods are provided for the synthesis of polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and receptor-~binding antagonists thereof, which conjugates retain unusually high receptor~-binding activity. Preparation of polymer conjugates according to the methods of the present invention diminishes or avoids steric inhibition of receptor-~ligand interactions that commonly results from the attachment of polymers to receptor-binding regions of cytokines, chemokines, growth factors and polypeptide hormones, as well as to agonistic and antagonistic analogs thereof. The invention also provides conjugates and compositions produced by such methods.  The conjugates of the present invention retain a higher level of receptor-binding activity than those produced by traditional polymer coupling methods that are not targeted to avoid receptor-binding domains of cytokines, chemokines, growth factors and polypeptide hormones. The conjugates of the present invention also exhibit an extended half-life in vivo and in vitro compared to unconjugated cytokines, chemokines, growth factors and polypeptide hormones. The present invention also provides kits comprising such conjugates and/or compositions, and methods of use of such conjugates and compositions in a variety of diagnostic, prophylactic, therapeutic and bioprocessing applications.
This work was developed in the island of Tenerife (Spain) within a public service specialised in labour integration of people with disabilities in which an IPS team was set up in 2005. The study was carried out in collaboration with the units of community mental health of the island. These units carry out the control of people with serious mental illnesses including pharmacological treatment and psychosocial programming. All research procedures were approved by the Medicine Committee of Canary Health Services.

The follow-up period for the data collection was set between 2013 and 2014. Employment specialists belong to a public institution specialized in work disability.Sixty-five participants but only 57 signed written informed consent and completed the baseline. Two groups were assigned randomly:one with support employment and cognitive rehabilitation the second group with IPS alone
A method and apparatus of detecting a bio-emergency, including receiving patient health information at a plurality of health care facilities. The patient health information, preferably triage data, is transmitted simultaneously with the receiving step to a bio-surveillance network for pooling and further analysis. In particular, the patient health information is then compiled to create, for example, volumetric health data. The information preferably is transmitted over a multi-level network including a number of local health care facilities such as hospital emergency rooms, a number of regional repositories such as regional health departments, and a centralized recipient such as the CDC. The local health care facilities communicate vertically with the regional repositories that, in turn, communicate vertically with the centralized recipient and possibly horizontally with other regional repositories. The centralized recipient can then transmit related information such as a health warning to the other members of the network and/or to other authorities.
A Legionella specific antibiotic AL072, a Streptomyces sp. AL91 producing the antibiotic, and a process for producing the antibiotic are disclosed. Further, the antibiotic compound has a specified formula. The formula is ##STR1## In addition the process also includes extraction of a culture broth provided by cultivating the microorganism Streptomyces sp. AL91, accession number KCCM 10055, with isopropyl alcohol and ethyl acetate to obtain an extract containing the antibiotic compound. The compound is then isolated from the extract by chromatography on a column filled with octadecyl silica gel and also by high pressure liquid chromatography.